SEC Comment Letter for Celularity (CELU) — Dec 23, 2025
Celularity Inc
Date: Dec. 23, 2025 · CIK: 0001752828 · Accession: 0000000000-25-011802
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292288
Letter
Re: Celularity Inc. Registration Statement on Form S-1 Filed December 19, 2025 File No. 333-292288 Dear Robert J. Hariri M.D., Ph.D.:
December 23, 2025
Robert J. Hariri, M.D., Ph.D. Chief Executive Officer and Chairman Celularity Inc. 170 Park Avenue Florham Park, New Jersey 07932
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Nazia J. Khan, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> December 23, 2025 Robert J. Hariri, M.D., Ph.D. Chief Executive Officer and Chairman Celularity Inc. 170 Park Avenue Florham Park, New Jersey 07932 Re: Celularity Inc. Registration Statement on Form S-1 Filed December 19, 2025 File No. 333-292288 Dear Robert J. Hariri M.D., Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nazia J. Khan, Esq. </TEXT> </DOCUMENT>